Supplementary Figure 7 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 76K, B-RAFi and MEKi combinatorial treatments lead to strong synergistic growth inhibition of V600EB-RAF cell lines regardless of concurrent P124SMEK1 expression. M229 and M238 vector vs. MEK1 stable cell lines were cultured with different levels of doxycycline (ng/ml), treated with constant ratios of B-RAFi (vemurafenib) and MEK1/2i (selumetinib), as indicated (muM), and measured for survival after 72h. Relative synergy of indicated drug combinations (expressed as log10 of CI values) is shown. Calculations were made by CalcuSyn software using the method of Chou and Taladay. Interpretation of CI values is summarized as follows: CI < 0.1 (very strong synergy); = 0.1-0.3 (strong synergy); = 0.3-0.7 (synergy); 0.7-0.85 (moderate synergy); = 0.85-0.9 (slight synergy); = 0.90-1.10 (nearly additive); and = 1.10-1.20 (slight antagonism). The relevant correlated Log10 (CI) values are shown as follow: Log10 (CI 0.1) = -1; Log10 (CI 0.3) = -0.5228787452803376; Log10 (CI 0.7) = -0.1549019599857432, and Log10 (CI 0.85) = -0.07058107428570727.
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362543147